文献速递肿瘤 PET/CT核素与放射性配体治疗

晚期黑色素瘤免疫治疗启动后CD8 T细胞变化的异质性

Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy.
PubMed 文献 · J Nucl Med · 2025-09-02

研究对免疫治疗初治的IV期黑色素瘤患者,在基线及免疫治疗开始后6-8周行89ZED88082A(CD8抗体示踪剂)全身PET显像,评估病灶及健康组织摄取变化。结果显示肿瘤摄取在治疗前后无显著变化(几何均值SUVmax 7.2 vs 7.3,P=0.89),但存在空间和时间异质性,且摄取变化与肿瘤反应不相关。

要点

  • 89ZED88082A PET可检测黑色素瘤病灶CD8 T细胞的空间和时间异质性。
  • 治疗前后肿瘤几何均值SUVmax分别为7.2和7.3(P=0.89),无显著变化。
  • 肿瘤摄取变化与iRECIST评估的肿瘤反应不相关。

核心结论

  • 黑色素瘤病灶中89ZED88082A摄取在患者内和患者间存在空间和时间异质性。
  • 治疗期间肿瘤摄取变化确实发生,但与肿瘤反应不相关。

研究设计与样本

  • 免疫治疗初治的IV期黑色素瘤成人患者接受89ZED88082A(10 mg静脉给药)PET扫描,基线及标准免疫治疗开始后6-8周各一次。
  • 11例入组患者中10例完成系列显像。
  • 肿瘤反应依据iRECIST 1.1版评估。

主要发现

  • 肿瘤几何均值SUVmax治疗前为7.2(95%CI 5.6-9.4),治疗期间为7.3(95%CI 5.7-9.5;P=0.89)。
  • 健康组织中脾脏摄取最高,治疗期间该值保持相似。
  • 免疫治疗后2例完全缓解、7例部分缓解、2例疾病进展。
  • 9例可评估的治疗前肿瘤组织显示CD8炎症免疫表型。

关键数值与推荐

  • CD8 PET示踪剂为89ZED88082A,静脉给予10 mg,给药后2天行PET扫描。
  • 肿瘤摄取以每例患者几何均值SUVmax表示,健康组织以所有患者SUVmean表示。
  • 肿瘤反应按iRECIST 1.1版评估。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 11例入组患者中仅10例完成系列显像。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Whole-body CD8+ T-cell PET imaging can detect spatial and temporal localization of CD8+ T cells. To obtain insight into early CD8+ T-cell response to immunotherapy in patients with melanoma, a highly immunogenic tumor, we performed serial PET imaging with the 1-armed CD8 antibody tracer 89ZED88082A. Methods: Immunotherapy-naïve adult patients with stage IV melanoma underwent PET scanning 2 d after receiving 10 mg of 89ZED88082A intravenously at baseline and 6-8 wk after initiation of standard-of-care immunotherapy. Tracer uptake in lesions, normal lymph nodes, and Waldeyer ring was assessed using SUVmax; other healthy tissue uptake was assessed using SUVmean Uptake in tumors and healthy lymph nodes was expressed as the geometric mean SUVmax per patient and in healthy tissue as SUVmean for all patients. Tumor response was evaluated in accordance with iRECIST version 1.1. Tumor tissue was immunohistochemically stained for CD8. Results: Serial imaging was performed for 10 of 11 enrolled patients. The geometric mean tumor SUVmax was 7.2 (95% CI, 5.6-9.4) before treatment and 7.3 (95% CI, 5.7-9.5; P = 0.89) during treatment, with spatial and temporal heterogeneity in tumor uptake. The spleen demonstrated the highest uptake among healthy tissues, and this value remained similar during treatment. After immunotherapy, 2 patients experienced a complete response, 7 a partial response, and 2 progressive disease. Changes in tumor uptake during treatment did occur but did not correlate with tumor response. Nine evaluable pretreatment tumor tissues showed a CD8-inflamed immune phenotype. Conclusion: Lesions demonstrated spatial and temporal heterogeneity in 89ZED88082A uptake within and among patients with melanoma.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hooiveld-Noeken JS, de Ruijter LK, van de Donk PP, et al. Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy. J Nucl Med. 2025. PMID: 40610232. doi:10.2967/jnumed.124.269313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。